Total Population
MASTER DAPT has met the three coprimary endpoints:
Discontinuation of DAPT 1 month after the implantation of an Ultimaster™ family DES was non-inferior to the continuation of DAPT for ≥2 additional months with regard to net adverse clinical events and major adverse cardiac or cerebral events. Furthermore, abbreviated DAPT was superior to standard-therapy DAPT with regards to major or clinically relevant nonmajor bleeding.
See the full results on Total Population
